The Netherlands ∙ Proposed Solutions to Tackle Expensive Medicines in The Netherlands: A Critical Review

If you have an interest in Life Sciences, I am glad to draw your attention to my Report in the latest edition of the European Pharmaceutical Law Review (EPLR). As many of you know, the cost of medicines is a frequent subject of debate in the Netherlands. In order to find solutions to this recurring issue, a report was published by the Council for Public Healthcare and Society (RVS), proposing compulsory patent licensing and the wider application of the compounding exemption (formula magistralis) as possible solutions. Please find my (critical) review here.


Navigate through our knowledgebase

Related articles

Article

International reliance

I have done more traveling than I probably should have in January and February between the US, the Middle East and various places in Europe. One of the constant themes was the…

Read more

Article

Happy 2025 – more churn for MDR and IVDR!

Happy new year everyone! I hope you had a good rest over the holidays because 2025 will be interesting. I am planning to revive this blog this year and hope to put…

Read more

Article

Happy 2025 – more churn for MDR and IVDR!

Happy new year everyone! I hope you had a good rest over the holidays because 2025 will be interesting. I am planning to revive this blog this year and hope to put new energy in it by making it more periodical with smaller bits of information and shorter analysis. You will still get my unique […]